TRAIL antibody (mAb) (Clone 55B709.3)

Host / Isotype

Mouse / IgG1

Reactivity

Human

Applications

WB

CloneNo.

55B709.3

Cat No : 40966 40966

Synonyms

TRAIL, TNF-Related Apoptosis-Inducing Ligand, TNFSF10, CD253, Apo2L, tumor necrosis factor ligand superfamily member 10, antibody, antibodies, monoclonal, 40966



产品信息

Tested Applications WB

Applications Validated by Active Motif: WB: 1 - 2 ug/ml dilution For optimal results, primary antibody incubations should be performed at room temperature. The addition of 0.1% Tween 20 to all blocking solutions may also reduce background. Individual optimization may be required.

Tested Reactivity Human
Host / Isotype Mouse / IgG1
Class Monoclonal
Type Antibody
Immunogen This TRAIL antibody was raised against a peptide corresponding to amino acid residues 17-35 of human TRAIL.
Full Name TRAIL antibody (mAb) (Clone 55B709.3)
Synonyms TRAIL, TNF-Related Apoptosis-Inducing Ligand, TNFSF10, CD253, Apo2L, tumor necrosis factor ligand superfamily member 10, antibody, antibodies, monoclonal, 40966
Molecular weight 32 kDa
GenBank accession numberNP_003801
RRIDAB_2793462
Purification Method Affinity Purified
Buffer PBS containing 0.02% sodium azide. Sodium azide is highly toxic.
Storage Some products may be shipped at room temperature. This will not affect their stability or performance. Avoid repeated freeze/thaw cycles by aliquoting items into single-use fractions for storage at -20°C for up to 2 years. Keep all reagents on ice when not in storage.

背景介绍

TRAIL (TNFSF10, CD253, Apo2L) is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. TRAIL is an acronym for TNF-Related Apoptosis-Inducing Ligand. Both the transmembrane and soluble recombinant forms of TRAIL can rapidly induce apoptosis in a wide variety of transformed and tumor cell lines, yet no cytotoxicity is observed with normal human cell lines, even though TRAIL and its receptors are expressed at significant levels there, and in most normal tissues in vitro. TRAIL is expressed constitutively in many tissues such as liver, lung, placenta, kidney, spleen, peripheral lymphocyte, etc. The binding of TRAIL to its receptors has been shown to trigger the activation of MAPK8/JNK, Caspase-3, and Caspase-8. TRAIL induces cancer apoptosis independently of p53 gene mutations. Two additional TRAIL decoy receptors (DcR1 and DcR2) do not trigger an apoptotic signal in normal cells and have been proposed to confer protection from TRAIL-inducing apoptosis. TRAIL may also play roles in immune responses, autoimmune disorders and HIV infection. TRAIL can interact with five different members of the TNF receptor superfamily, two of which contain a death domain, and can mediate an apoptotic response. TRAIL may also be a marker for progression of cancers.